Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Immuron Ltd ADR (IMRN)

Immuron Ltd ADR (IMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing ACCESSWIRE - Tue Dec 3, 9:45AM CST

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit...

IMRN : 2.02 (-1.32%)
ULY : 0.5300 (-6.85%)
IMUX : 1.2200 (-2.40%)
NMTC : 0.6000 (-6.06%)
SNGX : 3.20 (+1.59%)
TMG.VN : 0.190 (-2.56%)
BLGO : 0.1915 (-1.03%)
FET : 14.86 (-0.87%)
ACFN : 19.2500 (+6.94%)
NRBO : 2.36 (+0.43%)
TGCB : 0.0950 (-17.39%)
SOTK : 4.81 (+1.27%)
Immuron Limited CEO to Present at Small Cap Growth Virtual Investor Conference on December 5, 2024 Quiver Quantitative, Inc. - Mon Dec 2, 3:12PM CST

Immuron Limited CEO Steven Lydeamore will present at the Small Cap Growth Virtual Investor Conference on December 5, 2024.Quiver AI SummaryImmuron Limited announced that CEO Steven Lydeamore will present...

IMRN : 2.02 (-1.32%)
Immuron Limited Announces Participation in the LD Micro Main Event XVI Newsfile - Mon Sep 18, 2023

Presentation on Wednesday, October 4th at 11:00 PTMelbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical...

IMRN : 2.02 (-1.32%)
Immuron Limited Announces Participation in the LD Micro Invitational XIII Newsfile - Tue May 16, 2023

Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset...

IMRN : 2.02 (-1.32%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027 FinancialNewsMedia - Tue May 9, 2023

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.080 (-5.88%)
SILO : 0.9300 (-4.02%)
LLY : 825.62 (-0.51%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.6800 (-6.67%)
IMRN : 2.02 (-1.32%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027 PR Newswire - Tue May 9, 2023

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 0.9300 (-4.02%)
LLY : 825.62 (-0.51%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.6800 (-6.67%)
IMRN : 2.02 (-1.32%)
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic Globe Newswire - Tue Jul 26, 2022

MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on...

IMRN : 2.02 (-1.32%)
IMC.AX : 0.080 (-5.88%)
Immuron North American Travelan® Sales up 494% and Global sales up 431% Globe Newswire - Mon Jul 11, 2022

Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by...

IMRN : 2.02 (-1.32%)
IMC.AX : 0.080 (-5.88%)
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease Globe Newswire - Thu Jul 7, 2022

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on...

IMRN : 2.02 (-1.32%)
IMC.AX : 0.080 (-5.88%)
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic Globe Newswire - Wed May 11, 2022

Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical...

IMRN : 2.02 (-1.32%)
IMC.AX : 0.080 (-5.88%)

Barchart Exclusives

Is It Time to Invest in Lululemon Stock's Comeback Story? Barchart - 1 minute ago
Lululemon has staged a remarkable recovery in recent months. Over the past three months, the stock has rebounded by more than 35%, signaling investor confidence in its long-term potential. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot